Excerpt
The National Academies Roundtable on Genomics and Precision Health, in collaboration with the National Cancer Policy Forum, hosted a public workshop that examined how genomic data are used in health care, outside of the traditional settings for clinical genetics. The workshop identified opportunities for advancement of precision health care delivery. The event also explored how patients, clinicians, and payers assess and act upon the risks and benefits of genomic screening and diagnostic testing. Discussions focused on strategies to ensure that genomic applications are responsibly and equitably adopted to benefit populations as well as individuals over time. This Proceedings of a Workshop summarizes content from the event.
Copyright 2023 by the National Academy of Sciences. National Academies of Sciences, Engineering, and Medicine and National Academies Press and the graphical logos for each are all trademarks of the National Academy of Sciences. All rights reserved.
Grants and funding
This activity was supported by contracts between the National Academy of Sciences and Air Force Medical Service (Contract No. FA8052-17-P-0007); Centers for Disease Control and Prevention (Contract No. 75D30121D11240, Task Order No. 75D30121F00002); Health Resources and Services Administration (Contract No. HHSH250201500001I, Task Order No. 75R60220F34021); National Institutes of Health (Contract No. HHSN263201800029I, Task Order Nos. HHSN26300010 and HHSN26300008): All of Us Research Program, National Cancer Institute, National Human Genome Research Institute, National Institute of Mental Health, National Institute of Nursing Research, and National Institute on Aging; 23andMe, Inc.; American Academy of Nursing; American Association for Cancer Research; American Cancer Society; American College of Medical Genetics and Genomics; American College of Radiology; American Medical Association; American Society of Clinical Oncology; American Society of Human Genetics; Association for Molecular Pathology; Association of American Cancer Institutes; Association of Community Cancer Centers; Biogen; Blue Cross and Blue Shield Association; Bristol Myers Squibb; Cancer Support Community; College of American Pathologists; Eisai Inc.; Flatiron Health; Geisinger; Genome Medical, Inc.; Helix; Illumina, Inc.; The Jackson Laboratory (JAX); Kaiser Foundation Health Plan, Inc.; Merck & Co., Inc.; Myriad Genetics; National Comprehensive Cancer Network; National Patient Advocate Foundation; National Society of Genetic Counselors; Novartis Oncology; Oncology Nursing Society; Partners in Health; Pfizer, Inc.; Regeneron; Sanofi; Society for Immunotherapy of Cancer; The University of Vermont Health Network Medical Group; University of California, San Francisco; and Vibrent Health. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.